FIELD: organic chemistry.
SUBSTANCE: invention relates to a heterocyclic compound of formula IV or a pharmaceutically acceptable salt thereof, wherein L1-L2 is 
, where R1 is a substitute for nitrogen; Z is -NH-; R1 is selected from: 
and 
; R2 is methylpyridinyl or trifluoromethylpyridinyl; R4 denotes hydrogen; R5, R6 and R7 are selected from hydrogen, halogen and -OR1a, provided that one of R5, R6 and R7 is -OR1a; and R1a is selected from trifluoromethyl, 
. Invention also relates to specific compounds of formulas D1 and D8, a pharmaceutical composition based on said compounds and a method of treating, preventing or alleviating said diseases.
EFFECT: obtaining novel benzimidazole derivatives effective in treating cancer.
15 cl, 2 tbl, 30 ex
| Title | Year | Author | Number |
|---|---|---|---|
| (ALPHA-SUBSTITUTED ARALKYLAMINO- AND HETEROARYLALKYLAMINO)PYRIMIDINYL- AND 1,3,5-TRIAZINYLBENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF IN TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2608742C2 |
| 5,5-CONDENSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | 2010 |
|
RU2554087C2 |
| ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2539591C2 |
| 2,5-DISUBSTITUTED ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2532515C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| PYRROLO[2,3-B]PYRIDINE DERIVATIVE AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2418800C2 |
| CFTR REGULATORS AND THEIR APPLICATION METHODS | 2016 |
|
RU2749834C2 |
| MMPL3 INHIBITORS, COMPOSITIONS BASED ON THEM AND WAYS OF THEIR APPLICATION | 2019 |
|
RU2795229C2 |
| NOVEL COMPOUNDS | 2016 |
|
RU2734256C2 |
| CFTR REGULATORS AND METHODS FOR USE THEREOF | 2016 |
|
RU2742934C2 |
